Simon Langer
University of Würzburg
4 Papers
2 Citations
Simon Langer is an academic researcher from University of Würzburg. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Experimental heart failure causes depression-like behavior together with differential regulation of inflammatory and structural genes in the brain
Anna Frey,Sandy Popp,Antonia Post,Simon Langer,Marc Lehmann,Ulrich Hofmann,Anna-Leena Sirén,Leif Hommers,Angelika Schmitt,Tatyana Strekalova,Georg Ertl,Klaus-Peter Lesch,Klaus-Peter Lesch,Stefan Frantz +13 more
TL;DR: After induction of ischemic CHF, mice exhibited anhedonic behavior, decreased exploratory activity and interest in novelty, and cognitive impairment analogous to symptoms observed in humans with CHF and comorbid depression.
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
Johannes Levin,Nand Sing,Sue Melbourne,Amber Morgan,Carla Mariner,Maria Grazia Spillantini,Michal Wegrzynowicz,Jeffrey W. Dalley,Simon Langer,Sergey Ryazanov,Andrei Leonov,Christian Griesinger,Felix Schmidt,Daniel Weckbecker,Kai Prager,Torsten Matthias,Armin Giese +16 more
TL;DR: Anle138b was studied in a single-centre, double-blind, randomised, placebo-controlled single ascending dose and multiple ascending dose (MAD) study in healthy subjects as mentioned in this paper .
41
5-HTT Deficiency in Male Mice Affects Healing and Behavior after Myocardial Infarction.
Sandy Popp,Angelika G. Schmitt-Böhrer,Simon Langer,Ulrich Hofmann,Leif Hommers,Kai Schuh,Stefan Frantz,Klaus-Peter Lesch,Anna Frey +8 more
TL;DR: In this article, the role of 5-HTT deficiency on cardiac aging, and on healing and remodeling processes after myocardial infarction (MI), remains unclear, however, the authors have shown that deficiency leads to age-dependent cardiac dysfunction and disrupted early healing after MI probably due to alterations of inflammatory processes in mice.
5
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Florence Atrafi,Oliver Boix,Vivek Subbiah,Jennifer R. Diamond,Sant P. Chawla,Anthony W. Tolcher,Patricia LoRusso,Joseph Paul Eder,Martin Gutierrez,Kumar Sankhala,P. T. Ravi Rajagopalan,I. Genvresse,Simon Langer,Ron H.J. Mathijssen,Jaap Verweij,Ingmar Bruns,Martijn P. Lolkema +16 more